Can Avigan Bite Into Buzzing Indian Favipiravir Market?
Executive Summary
Fujifilm Toyama’s favipiravir may be relatively late on the Indian market,but local partner Dr Reddy’s believes that the large amount of safety data and superior shelf life of the product will hold it in good stead amid heightened competition. Local manufacturing could also help Dr Reddy’s pare the price differential with other versions.
You may also be interested in...
Dr Reddy’s To Steer Russian COVID-19 Vaccine Plans In India
Dr Reddy’s combines forces with the Russian Direct Investment Fund for clinical trials and supply of Sputnik V in India, amid what it views as “very important” data points in early studies of the COVID-19 vaccine.
Coronavirus Update: Roche's Actemra Fails In Phase III COVID Study
Disappointment as Roche/Chugai antibody tocilizumab misses most endpoints.
Coronavirus Update: Favipiravir Scores In Phase III Trial
Glenmark's Phase III trial of the antiviral points to efficacy in mild-to-moderate COVID-19, but many physicians in India remain skeptical.
Need a specific report? 1000+ reports available Buy Reports